Cited by 4Cancer Immunotherapy and BiomarkersBioinformatics and Genomic NetworksComputational Drug Discovery Methods

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

PathNetDRP: a novel biomarker discovery framework using pathway and protein–protein interaction networks for immune checkpoint inhibitor response prediction

Open access
Lee, Dohee, Ahn, Jaegyoon, Choi, Jonghwan·2025·BMC Bioinformatics

Abstract

BACKGROUND: Predicting immune checkpoint inhibitor (ICI) response remains a significant challenge in cancer immunotherapy. Many existing approaches rely on differential gene expression analysis or predefined immune signatures, which may fail to capture the complex regulatory mechanisms underlying immune response. Network-based models attempt to integrate biological interactions, but they often lack a quantitative framework to assess how individual genes contribute within pathways, limiting the specificity and interpretability of biomarkers. Given these limitations, we developed PathNetDRP, a framework that integrates biological pathways, protein-protein interaction networks, and machine learning to identify functionally relevant biomarkers for ICI response prediction. RESULTS: We introduce PathNetDRP, a novel biomarker discovery approach that applies the PageRank algorithm to prioritize ICI-associated genes, maps them to relevant biological pathways, and calculates PathNetGene scores to quantify their contribution to immune response. Unlike conventional methods that focus solely on gene expression differences, PathNetDRP systematically incorporates biological context to improve biomarker selection. Validation across multiple independent cancer cohorts showed that PathNetDRP achieved strong predictive performance, with cross-validation the area under the receiver operating characteristic curves increasing from 0.780 to 0.940. Interestingly, PathNetDRP did not merely improve predictive accuracy; it also provided insights into key immune-related pathways, reinforcing its potential for identifying clinically relevant biomarkers. CONCLUSION: The biomarkers identified by PathNetDRP demonstrated robust predictive performance across cross-validation and independent validation datasets, suggesting their potential utility in clinical applications. Furthermore, enrichment analysis highlighted key immune-related pathways, providing a deeper understanding of their role in ICI response regulation. While these findings underscore the promise of PathNetDRP, future work will explore the integration of additional predictive features, such as tumor mutational burden and microsatellite instability, to further refine its applicability.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12859-025-06125-0

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 PathNetDRP Biomarker Identification Process. First, PageRank is applied to a PPI network to identify ICI-related genes. Next, ICI-related pathways are determined using these selected genes. Finally, the genes are evaluated within the identified pathways, PathNetGene scores are computed, and biomarkers are selected via Kolmogorov-Smirnov significance testing
Fig. 1 PathNetDRP Biomarker Identification Process. First, PageRank is applied to a PPI network to identify ICI-related genes. Next, ICI-related pathways are determined using these selected genes. Finally, the genes are evaluated within the identified pathways, PathNetGene scores are computed, and biomarkers are selected via Kolmogorov-Smirnov significance testingCC BY-NC-ND · PubMed Central
Fig. 2 Overview of the Three Key Processes in PathNetDRP: A Application of the PageRank algorithm on the interaction network to identify the top 2000 genes closely associated with ICI targets. B Identification of biological pathways significantly associated with the selected 2000 gene candidates. C Configuration of subnetworks for each identified pathway and calculation of PathNetGene scores, quantifying the relevance of each gene within the context of its pathway
Fig. 2 Overview of the Three Key Processes in PathNetDRP: A Application of the PageRank algorithm on the interaction network to identify the top 2000 genes closely associated with ICI targets. B Identification of biological pathways significantly associated with the selected 2000 gene candidates. C Configuration of subnetworks for each identified pathway and calculation of PathNetGene scores, quantifying the relevance of each gene within the context of its pathwayCC BY-NC-ND · PubMed Central
Fig. 3 Kaplan–Meier curves comparison between PathNetDRP and ICI drug targets. A Gide, B Liu, and C IMvigor210
Fig. 3 Kaplan–Meier curves comparison between PathNetDRP and ICI drug targets. A Gide, B Liu, and C IMvigor210CC BY-NC-ND · PubMed Central
Fig. 4 Receiver operating characteristic curves and areas under curves. A Gide, B Liu, C Kim, and D IMvigor210
Fig. 4 Receiver operating characteristic curves and areas under curves. A Gide, B Liu, C Kim, and D IMvigor210CC BY-NC-ND · PubMed Central
Fig. 5 A–C Log-rank test comparison with baseline biomarker identification methods. A Gide, B Liu, and C IMvigor210 datasets. D–F c-index Results Comparison with Baseline Biomarker Identification Methods. D Gide, E Liu, and F IMvigor210 datasets
Fig. 5 A–C Log-rank test comparison with baseline biomarker identification methods. A Gide, B Liu, and C IMvigor210 datasets. D–F c-index Results Comparison with Baseline Biomarker Identification Methods. D Gide, E Liu, and F IMvigor210 datasetsCC BY-NC-ND · PubMed Central
Fig. 6 Differential gene expression analysis on PathNetDRP miomarkers. A–C Biomarkers identified on Gide dataset, D Liu, C Kim, and D IMvigor210
Fig. 6 Differential gene expression analysis on PathNetDRP miomarkers. A–C Biomarkers identified on Gide dataset, D Liu, C Kim, and D IMvigor210CC BY-NC-ND · PubMed Central
Fig. 7 Functional interaction network with enriched reactome pathways on PathNetDRP biomarkers from the gide dataset. A Visualization of enriched Reactome pathways. B Comparison of IL2RB expression levels between responder (blue) and non-responder groups using a t-test. C Chi-square test assessing the association between IL2RB and HLA-A co-expression patterns and ICI response groups. High and low expression levels were defined based on mean values. D Kaplan-Meier survival analysis based on IL2RB and HLA-A expression levels
Fig. 7 Functional interaction network with enriched reactome pathways on PathNetDRP biomarkers from the gide dataset. A Visualization of enriched Reactome pathways. B Comparison of IL2RB expression levels between responder (blue) and non-responder groups using a t-test. C Chi-square test assessing the association between IL2RB and HLA-A co-expression patterns and ICI response groups. High and low expression levels were defined based on mean values. D Kaplan-Meier survival analysis based on IL2RB and HLA-A expression levelsCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 45

  1. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–50. · DOI · Paper page
  2. Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1–11. · DOI · Paper page
  3. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E. Nivolumab in previously untreated melanoma without braf mutation. N Engl J Med. 2015;372(4):320–30. · DOI · Paper page
  4. Ziogas DC, Theocharopoulos C, Koutouratsas T, Haanen J, Gogas H. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome? Cancer Treat Rev. 2023;113:102499. · DOI
  5. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. · DOI · Paper page
  6. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D. Pd-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. · DOI · Paper page
  7. Shum B, Larkin J, Turajlic S. Predictive biomarkers for response to immune checkpoint inhibition. In: Seminars in Cancer Biology, vol. 79, Amsterdam: Elsevier; 2022. pp. 4–17 · DOI
  8. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76. · DOI · Paper page
  9. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51. · DOI · Paper page
  10. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V. Ifn-$$\gamma$$-related mrna profile predicts clinical response to pd-1 blockade. J Clin Investig. 2017;127(8):2930–40. · DOI · Paper page
  11. Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, Watkins TB, Rosenthal R, Biswas D, Rowan A. Meta-analysis of tumor-and t cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021;184(3):596–614. · DOI · Paper page
  12. Harper J, Sainson RC. Regulation of the anti-tumour immune response by cancer-associated fibroblasts. In: Seminars in Cancer Biology, vol. 25, Elsevier; 2014. p. 69–77 · DOI
  13. Dancsok AR, Gao D, Lee AF, Steigen SE, Blay J-Y, Thomas DM, Maki RG, Nielsen TO, Demicco EG. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. Oncoimmunology. 2020;9(1):1747340. · DOI
  14. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B. Signatures of t cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8. · DOI · Paper page
  15. Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018;24(10):1545–9. · DOI
  16. Kang Y, Vijay S, Gujral TS. Deep neural network modeling identifies biomarkers of response to immune-checkpoint therapy. Iscience. 2022;25(5):104228. · DOI
  17. Kong J, Ha D, Lee J, Kim I, Park M, Im S-H, Shin K, Kim S. Network-based machine learning approach to predict immunotherapy response in cancer patients. Nat Commun. 2022;13(1):3703. · DOI · Paper page
  18. Zhao L, Qi X, Chen Y, Qiao Y, Bu D, Wu Y, Luo Y, Wang S, Zhang R, Zhao Y. Biological knowledge graph-guided investigation of immune therapy response in cancer with graph neural network. Brief Bioinform. 2023;24(2):023. · DOI
  19. Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, Burovski E, Peterson P, Weckesser W, Bright J. Scipy 1.0: fundamental algorithms for scientific computing in python. Nat Methods. 2020;17(3):261–72. · DOI · Paper page
  20. Seabold S, Perktold J. Statsmodels: econometric and statistical modeling with python. SciPy. 2010;7:1.
  21. Al-Labadi L, Zarepour M. Two-sample Kolmogorov-Smirnov test using a Bayesian nonparametric approach. Math Methods Statist. 2017;26:212–25. · DOI
  22. Lee JS, Nair NU, Dinstag G, Chapman L, Chung Y, Wang K, Sinha S, Cha H, Kim D, Schperberg AV. Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell. 2021;184(9):2487–502. · DOI
  23. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel Iii EE, Koeppen H, Astarita JL, Cubas R. Tgf$$\beta$$ attenuates tumour response to pd-l1 blockade by contributing to exclusion of t cells. Nature. 2018;554(7693):544–8. · DOI · Paper page
  24. Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171(4):934–49. · DOI · Paper page
  25. Prat A, Navarro A, Paré L, Reguart N, Galván P, Pascual T, Martínez A, Nuciforo P, Comerma L, Alos L. Immune-related gene expression profiling after pd-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Can Res. 2017;77(13):3540–50. · DOI · Paper page
  26. Kim ST, Cristescu R, Bass AJ, Kim K-M, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M. Comprehensive molecular characterization of clinical responses to pd-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–58. · DOI
  27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M. New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. · DOI · Paper page
  28. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P. String v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):607–13. · DOI · Paper page
  29. Gillespie M, Jassal B, Stephan R, Milacic M, Rothfels K, Senff-Ribeiro A, Griss J, Sevilla C, Matthews L, Gong C. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 2022;50(D1):687–92. · DOI
  30. Lakatos E, Williams MJ, Schenck RO, Cross WC, Househam J, Zapata L, Werner B, Gatenbee C, Robertson-Tessi M, Barnes CP. Evolutionary dynamics of neoantigens in growing tumors. Nat Genet. 2020;52(10):1057–66. · DOI
  31. Boudreau JE, Hsu KC. Natural killer cell education and the response to infection and cancer therapy: stay tuned. Trends Immunol. 2018;39(3):222–39. · DOI
  32. Gallegos CE, Michelin S, Dubner D, Carosella ED. Immunomodulation of classical and non-classical hla molecules by ionizing radiation. Cell Immunol. 2016;303:16–23. · DOI
  33. Lasfar A, Abushahba W, Balan M, Cohen-Solal KA. Interferon lambda: a new sword in cancer immunotherapy. J Immunol Res. 2011;2011(1):349575.
  34. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. Antitumor activity of ifn-$$\lambda$$ in murine tumor models. J Immunol. 2006;176(12):7686–94. · DOI
  35. Carosella ED, Rouas-Freiss N, Tronik-Le Roux D, Moreau P, LeMaoult J. Hla-g: an immune checkpoint molecule. Adv Immunol. 2015;127:33–144. · DOI
  36. LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED. Hla-g1-expressing antigen-presenting cells induce immunosuppressive cd4+ t cells. Proc Natl Acad Sci. 2004;101(18):7064–9. · DOI
  37. Bartolome J, Molto C, Benitez-Fuentes JD, Fernandez-Hinojal G, Manzano A, Perez-Segura P, Mittal A, Tamimi F, Amir E, Ocana A. Prognostic value of human leukocyte antigen g expression in solid tumors: a systematic review and meta-analysis. Front Immunol. 2023;14:1165813. · DOI
  38. Akhurst RJ, Hata A. Targeting the tgf$$\beta$$ signalling pathway in disease. Nat Rev Drug Discovery. 2012;11(10):790–811. · DOI · Paper page
  39. Ni Y, Soliman A, Joehlin-Price A, Rose PG, Vlad A, Edwards RP, Mahdi H. High tgf-$$\beta$$ signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition. NPJ precision oncology. 2021;5(1):101. · DOI
  40. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for rna-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):47–47. · DOI · Paper page
  41. Kolberg L, Raudvere U, Kuzmin I, Adler P, Vilo J, Peterson H. g: Profiler—interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res. 2023;51(W1):207–12. · DOI · Paper page
  42. Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T, Chang W. David: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):216–21. · DOI
  43. Jiang T, Zhou C, Ren S. Role of il-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):1163462. · DOI
  44. Raeber ME, Sahin D, Karakus U, Boyman O. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. EBioMedicine. 2023;90:104539. · DOI
  45. Wu X, Li T, Jiang R, Yang X, Guo H, Yang R. Targeting mhc-i molecules for cancer: function, mechanism, and therapeutic prospects. Mol Cancer. 2023;22(1):194. · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Lee, D., Ahn, J., & Choi, J.
Affiliations
  • Incheon National University (KR)
  • Hallym University (KR)
Corresponding author
  • Lee, Dohee
  • Ahn, Jaegyoon
  • Choi, Jonghwan
Venue
BMC Bioinformatics
Published
2025-05-05
Volume
26
Issue
1
Pages
119-119
ISSN
1471-2105 (ISSN-L)
OpenAlex
W4410078064
Cited by
4
References
3
Citations by year
2026: 4
FWCI
1.66
Type
journal article
Language
en
Open access
Locations
  • BMC Bioinformatics (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Ministry of Science and ICT, South Korea (IITP-2025-RS-2023-00260175, RS-2024-00345226)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
immune checkpoint inhibitor response prediction, biomarker discovery, protein-protein interaction network, pathway analysis, cancer immunotherapy, immune pathways
MeSH terms
Machine Learning, Immune Checkpoint Inhibitors, Algorithms, Humans, Neoplasms, Biomarkers, Tumor, Computational Biology, Protein Interaction Maps

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review